10 articles tagged with #clinical-trials. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
Researchers have developed ClinicalReTrial, a multi-agent AI system that can redesign clinical trial protocols to improve success rates. The system demonstrated an 83.3% improvement rate in trial protocols with a mean 5.7% increase in success probability at minimal cost of $0.12 per trial.
Researchers developed mCLM, a 3-billion parameter modular Chemical Language Model that generates functional molecules compatible with automated synthesis by tokenizing at the building block level rather than individual atoms. The AI system outperformed larger models including GPT-5 in creating synthesizable drug candidates and can iteratively improve failed clinical trial compounds.
Researchers analyzed ClinicalTrials.gov data to track AI adoption in clinical research, finding exponential growth in AI-related trials globally with machine learning, deep learning, and large language models increasingly prevalent. Using a hybrid human-AI screening approach, the study revealed that while AI and humans agreed on identifying non-AI studies, they diverged significantly on classifying human-AI interactions, highlighting the need for clearer trial reporting standards.
Researchers introduce SCENE, a multi-agent AI framework that transforms general biomedical knowledge into specific, evidence-supported hypotheses grounded in experimental data. The system successfully identifies patient subgroups with different treatment responses in clinical trials and context-specific biological responses in genomic studies, bridging the gap between broad theoretical knowledge and actionable dataset-specific insights.
Inhibrx Biosciences (INBX) stock surged 17% following positive Phase 2 clinical trial results showing that INBRX-106 combination therapy doubled response rates in head and neck cancer patients, demonstrating meaningful therapeutic efficacy.
Researchers developed a machine learning approach combining Virtual Twins method with survLIME to identify patient subgroups who respond differently to treatments in clinical trials. The method achieved 0.77 AUC for identifying treatment responders in colorectal cancer trials, finding genetic mutations, metastasis sites, and ethnicity as key response factors.
NVIDIA CEO Jensen Huang participated in a fireside chat at the J.P. Morgan Healthcare Conference, discussing AI applications across healthcare sectors including genomic research, drug discovery, clinical trials, and patient care. The discussion highlighted how AI is making significant inroads throughout the entire healthcare industry.
Researchers developed a machine learning framework to predict which clinical trials are likely to have high dosing error rates before the trials begin. The system analyzed 42,112 clinical trials and achieved 86.2% accuracy using a combination of structured data and text analysis, enabling proactive risk management in clinical research.
Paradigm, a healthcare company, is leveraging OpenAI's API to enhance patient access to clinical trials. This application demonstrates the practical use of AI technology in healthcare to address patient recruitment and trial participation challenges.
Researchers developed a knowledge graph framework that integrates diverse data sources to predict adverse drug reactions for protein kinase inhibitors. The system combines drug-target data, clinical literature, trial metadata, and safety reports into a unified network for better drug safety analysis and pharmacovigilance.
